UCB to divest mature neurology and allergy portfolio in China for $680m to CBC Group and Mubadala

UCB, a Belgian biopharmaceutical company, has announced the divestment of its mature neurology and allergy portfolio in China for $680 million, marking a strategic shift ... Read More